Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | FYN | P06241 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12547436 | 0.70 | — | — | |
| SCHEMBL23249333 | 0.67 | KMT2A (0.44) | LMNASMN1; SMN2GAAMAPTPOLB | |
| SCHEMBL28320299 | 0.67 | — | — | |
| SCHEMBL836636 | 0.66 | NPC1 (0.59) | LMNASMN1; SMN2GAAMAPTL3MBTL1 | |
| SCHEMBL844444 | 0.62 | L3MBTL1 (1.00) | LMNASMN1; SMN2GAAL3MBTL1POLB | |
| SCHEMBL7785889 | 0.62 | — | — | |
| SCHEMBL6926731 | 0.61 | — | — | |
| SCHEMBL22750790 | 0.61 | GLA (0.38) | KMT2A | |
| SCHEMBL11875668 | 0.61 | — | — | |
| SCHEMBL13738136 | 0.58 | GAA (1.00) | LMNASMN1; SMN2GAAMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954198-B2 | Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2021-03-23 | — | — | US | disclosed |
| EP-3115357-B1 | BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF PROTEIN MISFOLDING DISEASES | RES & INNOVATION UK (GB) | 2020-08-12 | — | — | EP | disclosed |
| US-20200095210-A1 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases | INFLECTIS BIOSCIENCE (FR) | 2020-03-26 | — | — | US | disclosed |
| US-20180354914-A1 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases | MEDICAL RESEARCH COUNCIL (GB) | 2018-12-13 | — | — | US | disclosed |
| US-10100020-B2 | Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2018-10-16 | — | — | US | disclosed |
| US-20170247344-A1 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2017-08-31 | — | — | US | disclosed |
| US-9682943-B2 | Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases | MEDICAL RESEARCH COUNCIL (GB) | 2017-06-20 | — | — | US | disclosed |
| EP-3115357-A1 | BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF PROTEIN MISFOLDING DISEASES | Medical Research Council (GB) | 2017-01-11 | — | — | EP | disclosed |
| EP-2943467-B1 | BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF PROTEIN MISFOLDING DISEASES | MEDICAL RES COUNCIL (GB) | 2016-07-13 | — | — | EP | disclosed |
| US-20160046589-A1 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2016-02-18 | — | — | US | disclosed |
| US-8143251-B2 | Triazolotriazines as kinase inhibitors | INCYTE CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110144113-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2011-06-16 | — | — | US | disclosed |
| US-7915408-B2 | Triazolotriazines as kinase inhibitors | INCYTE CORPORATION (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100130467-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2010-05-27 | — | — | US | disclosed |
| US-7683060-B2 | Triazolotriazines as kinase inhibitors | INCYTE CORPORATION (US) | 2010-03-23 | — | — | US | disclosed |
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | MET, ERBB2, RET | LMNA 4236/4885SMN1; SMN2 4495/4885FYN 482/4885 |
| US-20200095210-A1 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases | ATXN2L, BCL9L, ATXN10 | LMNA 3412/4885SMN1; SMN2 178/4885FYN 584/4885 |
| US-20170247344-A1 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases | ATXN2L, BCL9L, ATXN10 | LMNA 3412/4885SMN1; SMN2 178/4885FYN 584/4885 |
| US-20100130467-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | MET, ERBB2, RET | LMNA 4236/4885SMN1; SMN2 4495/4885FYN 482/4885 |
| US-10100020-B2 | Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases | ATXN2L, BCL9L, ATXN10 | LMNA 3412/4885SMN1; SMN2 178/4885FYN 584/4885 |
| US-20180354914-A1 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases | RTN3, ATXN2L, PARK7 | LMNA 3967/4885SMN1; SMN2 253/4885FYN 598/4885 |
| US-20110144113-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | MET, ERBB2, RET | LMNA 4236/4885SMN1; SMN2 4495/4885FYN 482/4885 |
| US-20160046589-A1 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases | ATXN2L, BCL9L, ATXN10 | LMNA 3412/4885SMN1; SMN2 178/4885FYN 584/4885 |
| US-10954198-B2 | Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases | ATXN2L, BCL9L, ATXN10 | LMNA 3412/4885SMN1; SMN2 178/4885FYN 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.